Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Recent & Breaking News (NDAQ:GRCE)

INVESTIGATION ALERT: Halper Sadeh LLP Investigates ACST, CLDR, DISCA, GRA, TRMT, XEC; Shareholders are Encouraged to Contact the Firm

PR Newswire July 3, 2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acasti Pharma, Inc. - ACST

PR Newswire July 3, 2021

Acasti Pharma Provides Fiscal 2021 Year-End Business Update

GlobeNewswire June 22, 2021

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

GlobeNewswire May 17, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm

PR Newswire May 13, 2021

ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST

Business Wire May 12, 2021

Acasti Pharma (TSXV:ACST) agrees to acquire Grace Therapeutics

Simon Druker  May 7, 2021

Acasti Pharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Acasti Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - ACST

Business Wire May 7, 2021

Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

GlobeNewswire May 7, 2021

Acasti Pharma (TSXV:ACST) provides update on financing activities

John Ballem  March 9, 2021

Acasti Pharma Provides Update on Recent Financing Activities

GlobeNewswire March 8, 2021

Acasti Pharma Announces Results for Third Quarter of Fiscal 2021

GlobeNewswire February 9, 2021

Acasti Pharma Provides Update on Recent Financing Activities

GlobeNewswire January 27, 2021

Acasti Pharma Unaware of Any Material Change

GlobeNewswire December 23, 2020

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021

GlobeNewswire November 16, 2020

Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM

GlobeNewswire October 1, 2020

Acasti Announces Review Process of Strategic Alternatives

GlobeNewswire September 29, 2020

Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer

GlobeNewswire September 16, 2020

Acasti Announces Filing and Mailing of Information Circular and Change in Record Date

GlobeNewswire September 11, 2020

Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia

GlobeNewswire August 31, 2020

Podcasts